Capricor Stock Rallies 20% on DMD Data Presentation Update
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $75
Gilead Sciences Analyst Ratings
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher Plant Making Astra/ Sanofi RSV Drug Reportedly Breached FDA Rules
Wells Fargo's 'Value Equity' Stocks: VZ, AZO, KR, and More
Market Whales and Their Recent Bets on REGN Options
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Avidity Gets FDA Partial Clinical Hold Lifted on DM1 Drug Candidate
Dianthus Started at Outperform by Oppenheimer on DNTH103 Opportunity
AstraZeneca Supplemental NDA for Calquence Accepted by FDA
BridgeBio Granted Perform Rating at Oppenheimer on Market Challenges
U.S. Tweaks 2025 Medicare Price Negotiation Process
The FDA Has Accepted And Granted Priority Review AstraZeneca's Supplemental New Drug Application For Calquence (Acalabrutinib) For Previously Untreated Mantle Cell Lymphoma, The FDA Action Date Is Anticipated During Q1 Of 2025
Dr. Reddy's Signs Voluntary Licensing Agreement With Gilead Sciences To Manufacture And Commercialise Lenacapavir In India And Other Countries
Gilead Signs Deals With Six Drugmakers for Generic Lenacapavir